ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN CLINICAL DATA MANAGEMENT: WORKFLOW AUTOMATION AND QUALITY ENHANCEMENT

Abstract

Clinical data management (CDM) is the backbone that converts raw trial and real-world observations into a validated, analysis-ready dataset, and its quality directly determines the reliability of clinical and regulatory decisions. Traditional CDM workflows, however, remain heavily manual, relying on rule-based edit checks, page-by-page source data verification, and human medical coding, all of which are labour intensive, error prone, and slow relative to the pace of modern trials and the growing volume of electronic health record (EHR), registry, wearable, and multi-omics data. This paper examines how artificial intelligence (AI) and machine learning (ML) are reshaping CDM by automating repetitive workflow steps and elevating data quality beyond what manual processes can achieve. We review the principal AI/ML techniques applied in this domain, including natural language processing (NLP) for unstructured clinical text, supervised and unsupervised ML for anomaly and outlier detection, predictive models for query triage and risk-based monitoring, and robotic process automation (RPA) for system-to-system data reconciliation. A conceptual framework is presented that links data ingestion, model-assisted cleaning, human-in-the-loop review, and continuous learning, and this is discussed alongside emerging regulatory expectations for AI/ML-based tools, including the U.S. Food and Drug Administration's Total Product Life Cycle (TPLC) approach and Good Machine Learning Practice (GMLP) principles. We further discuss quality enhancement mechanisms such as automated query generation, intelligent medical coding, real-time anomaly flags, and risk-based monitoring, and we consider the operational, ethical, and validation challenges that must be addressed before such systems can be trusted at scale. The paper concludes that AI/ML, when embedded within a governed, human-supervised workflow, can substantially reduce cycle times and error rates in CDM while introducing new categories of risk that require proactive, lifecycle-based oversight.